Home
>
National Drug Code (NDC)
>
ORENCIA
ORENCIA - 0003-2187-10 - (abatacept)
Drug Information of ORENCIA
| Product NDC: | 0003-2187 |
| Proprietary Name: | ORENCIA |
| Non Proprietary Name: | abatacept |
| Active Ingredient(s): | 250 mg/15mL & nbsp; abatacept |
| Administration Route(s): | INTRAVENOUS |
| Dosage Form(s): | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of ORENCIA
| Product NDC: | 0003-2187 |
| Labeler Name: | E.R. Squibb & Sons, L.L.C. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | BLA125118 |
| Marketing Category: | BLA |
| Start Marketing Date: | 20090101 |
Package Information of ORENCIA
| Package NDC: | 0003-2187-10 |
| Package Description: | 1 VIAL, SINGLE-USE in 1 CELLO PACK (0003-2187-10) > 15 mL in 1 VIAL, SINGLE-USE |
NDC Information of ORENCIA
| NDC Code | 0003-2187-10 |
| Proprietary Name | ORENCIA |
| Package Description | 1 VIAL, SINGLE-USE in 1 CELLO PACK (0003-2187-10) > 15 mL in 1 VIAL, SINGLE-USE |
| Product NDC | 0003-2187 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | abatacept |
| Dosage Form Name | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Route Name | INTRAVENOUS |
| Start Marketing Date | 20090101 |
| Marketing Category Name | BLA |
| Labeler Name | E.R. Squibb & Sons, L.L.C. |
| Substance Name | ABATACEPT |
| Strength Number | 250 |
| Strength Unit | mg/15mL |
| Pharmaceutical Classes | Decreased Cytokine Activity [PE],Selective T Cell Costimulation Modulator [EPC],Recombinant Fusion Proteins [Chemical/Ingredient] |
